SCreening for Anti-Neuroinflammation Molecular Entities
A humanized neuroinflammation in vitro platform
Scale up human disease models with unmatched cellular quality and disease relevance to increase confidence in clinical translation and make meaningful drug discovery and development decisions.
*Powered by axoCells™ - the leading choice for functionally relevant human iPSC-derived cells (or customer's preferred source)
Ask us about the benefits of SCANME, today.
SCANME
Time to Humanize
Human disease models are crucial for addressing the complexities of treating neurodegenerative disorders. SCANME provides researchers with access to biologically relevant human cell types and unrivalled scalability. Discover what sets SCANME apart in this video...
Leverage the features of SCANME
Customize SCANME's full suite of capabilities to meet your research needs. From target validation and hypothesis testing in human cell models to deepening SAR understanding, uncovering mechanisms of action, and exploring novel biological pathways.
*Powered by axoCells™ - the leading choice for functionally relevant human iPSC-derived cells (or customer's preferred source)
Why SCANME for your drug discovery program?
SCANME redefines the use of humanized in vitro assays for drug discovery. Unlock its potential, today.
A History of Innovation
Since 2011, the integrated drug discovery team at Sygnature Discovery has delivered over 40 preclinical compounds and 25 clinical compounds. Our scientists are named on over 170 customer patent applications.
